ASCO 2026 Highlights

References

1. Wolpin, B. M. et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. J Clin Oncol 44, LBA5–LBA5 (2026).
2. Cameron, J. M. et al. Global validation of a brain cancer liquid biopsy. J Clin Oncol 44, 2052–2052 (2026).
3. Robert de Massy, M. et al. Multi-modal AI modeling to predict clinical trial outcomes and benchmarks pan-RAS versus KRAS G12D inhibition in KRAS G12D–mutant PDAC. J Clin Oncol 44, 4020–4020 (2026).
4. Conroy, M. R. et al. Prophylactic peptide vaccine targeting resistance mutations in advanced ALK-positive lung cancer: Primary analysis from the ARCHER trial. J Clin Oncol 44, 8517–8517 (2026).
5. Choi, B. D. et al. Rituximab pre-conditioning in a phase I study of CARv3-TEAM-E for recurrent glioblastoma (GBM): The INCIPIENT trial. J Clin Oncol 44, 2059–2059 (2026).
6. Orland, M. D. et al. Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. J Clin Oncol 44, 3143–3143 (2026).
7. Dickson, M. A. et al. SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. J Clin Oncol 44, LBA2–LBA2 (2026).
8. Conley, A. P. et al. Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL. J Clin Oncol 44, 11511–11511 (2026).
9. Schmid, P. et al. Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status. J Clin Oncol 44, 502–502 (2026).
10. Wu, Y.-L. et al. Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med https://doi.org/10.1056/NEJMoa2602628 (2026) doi:10.1056/NEJMoa2602628.
11. McKay, R. R. et al. Quality of life analysis from a multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 versus radium-223 in metastatic castration-resistant prostate cancer with bone metastases (COMRADE). J Clin Oncol 44, 5040–5040 (2026).
12. Cescon, D. W. et al. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study. J Clin Oncol 44, 1002–1002 (2026).